Advanced search
Publication Cover
Future Oncology Volume 17, 2021 - Issue 35
Submit an article Journal homepage
1,702
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Burden of Illness and Outcomes in Second-Line Large B-Cell Lymphoma Treatment: Real-World Analysis of Medicare Beneficiaries

Karl M Kilgore1 Avalere Health, An Inovalon Company,Washington,DC 20005,USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1103-2107View further author information
ORCID Icon,
Iman Mohammadi1 Avalere Health, An Inovalon Company,Washington,DC 20005,USAView further author information
,
Anny C Wong1 Avalere Health, An Inovalon Company,Washington,DC 20005,USAORCID Iconhttps://orcid.org/0000-0001-7090-0563View further author information
ORCID Icon,
Julia T Snider2 Kite, A Gilead Company,Santa Monica,CA 90404,USAView further author information
,
Paul Cheng2 Kite, A Gilead Company,Santa Monica,CA 90404,USAView further author information
,
Amy Schroeder1 Avalere Health, An Inovalon Company,Washington,DC 20005,USAView further author information
&
Anik R Patel2 Kite, A Gilead Company,Santa Monica,CA 90404,USAView further author information
 show all
Pages 4837-4847 | Received 14 May 2021, Accepted 26 Aug 2021, Published online: 14 Oct 2021

References

  • National Cancer Institute . Surveillance, Epidemiology and End Results Program. Cancer stat facts: non-Hodgkin lymphoma (2021). https://seer.cancer.gov/statfacts/html/nhl.html
  • National Cancer Institute . Surveillance, Epidemiology and End Results Program. Cancer Stat Facts: NHL – diffuse large B-cell lymphoma (DLBCL) (2021). https://seer.cancer.gov/statfacts/html/dlbcl.html
  • National Comprehensive Cancer Network . B-Cell Lymphomas (version 4.2020) (2020). www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
  • Crump M , NeelapuSS, FarooqUet al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood130(16), 1800–1808 (2017).
  • Van Den Neste E , SchmitzN, MounierNet al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant.51(1), 51–57 (2016).
  • Galaznik A , HuelinR, StokesMet al. Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Future Sci. OA4(7), FSO322 (2018).
  • Snider JT , ChengP, SongX, McMorrowD, DiakunD. Lines of therapy in patients with relapsed or refractory large B-cell lymphoma and stem cell transplant-intended treatment. Blood136(Suppl. 1), 45–46 (2020).
  • Purdum A , TieuR, ReddySR, BroderMS. Direct costs associated with relapsed diffuse large B-cell lymphoma therapies. Oncologist24(9), 1229–1236 (2019).
  • Tkacz J , GarciaJ, GitlinMet al. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. Leuk. Lymphoma61(7), 1601–1609 (2020).
  • Deyo RA , CherkinDC, CiolMA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol.45(6), 613–619 (1992).
  • Quan H , SundararajanV, HalfonPet al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care43(11), 1130–1139 (2005).
  • Storti S , SpinaM, PesceEAet al. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a Phase II multicenter study of the Fondazione Italiana Linfomi. Haematologica103(8), 1345–1350 (2018).
  • Danese MD , GriffithsRI, GleesonMLet al. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy. Leuk. Lymphoma58(5), 1094–1104 (2017).
  • Cho SK , McCombsJ, PunwaniN, LamJ. Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States. Leuk. Lymphoma60(10), 2464–2470 (2019).
  • Preussler JM , FarniaSH, DenzenEM, MajhailNS. Variation in Medicaid coverage for hematopoietic cell transplantation. J. Oncol. Pract.10(4), e196–200 (2014).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.